221 related articles for article (PubMed ID: 10678362)
1. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
Westphal EM; Ge J; Catchpole JR; Ford M; Kenney SC
Cancer Gene Ther; 2000 Jan; 7(1):97-106. PubMed ID: 10678362
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Green NK; Youngs DJ; Neoptolemos JP; Friedlos F; Knox RJ; Springer CJ; Anlezark GM; Michael NP; Melton RG; Ford MJ; Young LS; Kerr DJ; Searle PF
Cancer Gene Ther; 1997; 4(4):229-38. PubMed ID: 9253508
[TBL] [Abstract][Full Text] [Related]
3. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
4. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.
Drabek D; Guy J; Craig R; Grosveld F
Gene Ther; 1997 Feb; 4(2):93-100. PubMed ID: 9081711
[TBL] [Abstract][Full Text] [Related]
5. Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
Benouchan M; Do Nascimento F; Perret GY; Colombo BM
Int J Oncol; 2006 Feb; 28(2):457-62. PubMed ID: 16391801
[TBL] [Abstract][Full Text] [Related]
6. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase.
Rogers RP; Ge JQ; Holley-Guthrie E; Hoganson DK; Comstock KE; Olsen JC; Kenney S
Hum Gene Ther; 1996 Dec; 7(18):2235-45. PubMed ID: 8953314
[TBL] [Abstract][Full Text] [Related]
7. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
[TBL] [Abstract][Full Text] [Related]
8. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
White CL; Menghistu T; Twigger KR; Searle PF; Bhide SA; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Mar; 15(6):424-33. PubMed ID: 18079753
[TBL] [Abstract][Full Text] [Related]
9. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
McNeish IA; Green NK; Gilligan MG; Ford MJ; Mautner V; Young LS; Kerr DJ; Searle PF
Gene Ther; 1998 Aug; 5(8):1061-9. PubMed ID: 10326029
[TBL] [Abstract][Full Text] [Related]
10. E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.
Blackwood L; O'Shaughnessy PJ; Reid SW; Argyle DJ
Vet J; 2001 May; 161(3):269-79. PubMed ID: 11352484
[TBL] [Abstract][Full Text] [Related]
11. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
Djeha AH; Hulme A; Dexter MT; Mountain A; Young LS; Searle PF; Kerr DJ; Wrighton CJ
Cancer Gene Ther; 2000 May; 7(5):721-31. PubMed ID: 10830719
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.
Plumb JA; Bilsland A; Kakani R; Zhao J; Glasspool RM; Knox RJ; Evans TR; Keith WN
Oncogene; 2001 Nov; 20(53):7797-803. PubMed ID: 11753658
[TBL] [Abstract][Full Text] [Related]
13. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.
Chung-Faye GA; Chen MJ; Green NK; Burton A; Anderson D; Mautner V; Searle PF; Kerr DJ
Gene Ther; 2001 Oct; 8(20):1547-54. PubMed ID: 11704815
[TBL] [Abstract][Full Text] [Related]
14. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
15. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
Grove JI; Lovering AL; Guise C; Race PR; Wrighton CJ; White SA; Hyde EI; Searle PF
Cancer Res; 2003 Sep; 63(17):5532-7. PubMed ID: 14500391
[TBL] [Abstract][Full Text] [Related]
16. E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.
Mitchell DJ; Minchin RF
Cancer Gene Ther; 2008 Nov; 15(11):758-64. PubMed ID: 18600257
[TBL] [Abstract][Full Text] [Related]
17. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.
Helsby NA; Atwell GJ; Yang S; Palmer BD; Anderson RF; Pullen SM; Ferry DM; Hogg A; Wilson WR; Denny WA
J Med Chem; 2004 Jun; 47(12):3295-307. PubMed ID: 15163209
[TBL] [Abstract][Full Text] [Related]
18. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.
Wilson WR; Pullen SM; Hogg A; Helsby NA; Hicks KO; Denny WA
Cancer Res; 2002 Mar; 62(5):1425-32. PubMed ID: 11888915
[TBL] [Abstract][Full Text] [Related]
20. Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro.
Nishihara E; Nagayama Y; Narimatsu M; Namba H; Watanabe M; Niwa M; Yamashita S
Anticancer Res; 1998; 18(3A):1521-5. PubMed ID: 9673364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
